Table 3. The clinical features of the 141 patients who treated with R-CHOP-like therapies.
| Characteristics | No. of cases (%) |
|---|---|
| Age (years) | |
| ≤ 60 | 82 (58.2) |
| Male | 92 (65.2) |
| Stage III–IV | 75 (53.2) |
| Elevated LDH | 58 (41.1) |
| ECOG PS ≥ 2 | 29 (20.6) |
| Extranodal sites ≥ 2 | 34 (24.1) |
| IPI score of 3–5 | 48 (34.0) |
| B symptoms | 52 (36.9) |
| COO (Hans) | |
| GCB | 63 (44.7) |
| Non-GCB | 78 (55.3) |
| Treatment | |
| R-CHOP | 72 (51.1) |
| R-DA-EPOCH | 22 (15.6) |
| R-CHOP-likeζ | 47 (33.3) |
| Prophylactic CNS treatment§ | 25 (17.7) |
| Radiation¶ | 12 (8.6) |
| Treatment response | |
| CR(u) | 112 (79.4) |
| PR | 14 (10.0) |
| SD/PD | 15 (10.6) |
Cases who received multiple regimens because of the following events: disease progression, cardiotoxicity of doxorubicin, accompanied hemophagocytic syndrome and extremely poor ECOG PS. The R-CHOP-like regimens including R-CDOP, R-CEOP and R-mini-CHOP.
Cases of with an increased risk of CNS events (paranasal sinus, testicular, bone marrow involvement) received 4–8 cycles of intrathecal methotrexate and/or cytarabine during the course of treatment.
Cases with localized lesion received radiotherapy alone or radioimmunotherapy.
Abbreviations: COO: cell of origin; CR(u): complete remission (unconfirmed); DLBCL: diffuse large B-cell lymphoma; ECOG PS: performance status of Eastern Cooperative Oncology Group; GCB: germinal-center B-cell type; IPI: International Prognostic Index; LDH: lactate dehydrogenase; PR: partial remission; SD/PD: stable disease/progression of disease.